Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
4.58 (USD) • At close June 6, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Omzet
| 203.07 | 163.914 | 110.248 | 49.59 | 49.59 | 20.155 | 2.465 | 1.556 | 1.075 |
| Kosten van de omzet
| 36.832 | 28.645 | 22.634 | 13.318 | 13.318 | 9.328 | 0.042 | 0.004 | 0.008 |
| Brutowinst
| 166.238 | 135.269 | 87.614 | 36.272 | 36.272 | 10.827 | 2.423 | 1.552 | 1.067 |
| Brutowinstmarge
| 0.819 | 0.825 | 0.795 | 0.731 | 0.731 | 0.537 | 0.983 | 0.997 | 0.993 |
| Onderzoek- en ontwikkelingskosten
| 25.56 | 22.341 | 20.966 | 25.16 | 25.16 | 20.921 | 40.654 | 20.166 | 10.238 |
| Algemene en administratieve kosten
| 0 | 0 | 0 | 0 | 0 | 0 | 21.113 | 8.015 | 4.06 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 163.481 | 146.095 | 137.745 | 125.718 | 125.718 | 73.732 | 21.113 | 8.015 | 4.06 |
| Overige kosten
| 10.843 | 10.843 | 10.843 | 0.55 | 0.55 | -0.28 | 0 | -0.001 | -0.005 |
| Bedrijfskosten
| 199.884 | 179.279 | 169.554 | 151.428 | 151.428 | 94.373 | 61.767 | 28.181 | 14.298 |
| Bedrijfsresultaat
| -33.646 | -44.01 | -81.94 | -115.156 | -115.156 | -83.546 | -59.344 | -26.629 | -13.231 |
| Bedrijfsresultaat ratio
| -0.166 | -0.268 | -0.743 | -2.322 | -2.322 | -4.145 | -24.075 | -17.114 | -12.308 |
| Totaal overige inkomsten en kosten netto
| -23.458 | -19.494 | -14.144 | -7.569 | -7.704 | -3.658 | -0.736 | 0.075 | 0.022 |
| Inkomen voor belasting
| -57.104 | -63.504 | -96.084 | -122.725 | -122.725 | -91.25 | -60.08 | -26.554 | -13.209 |
| Inkomen voor belasting ratio
| -0.281 | -0.387 | -0.872 | -2.475 | -2.475 | -4.527 | -24.373 | -17.066 | -12.287 |
| Belastingkosten
| -2.268 | -1.249 | -1.424 | 0 | -0.11 | -0.11 | 1.809 | 0.001 | -0.003 |
| Nettowinst
| -54.836 | -62.255 | -94.66 | -122.725 | -122.725 | -91.14 | -60.08 | -26.554 | -13.209 |
| Nettowinstmarge
| -0.27 | -0.38 | -0.859 | -2.475 | -2.475 | -4.522 | -24.373 | -17.066 | -12.287 |
| WPA (Winst Per Aandeel)
| -0.37 | -0.45 | -0.698 | -1.553 | -2.88 | -3.49 | -4.99 | -13.09 | -7.17 |
| Verwaterde WPA
| -0.37 | -0.45 | -0.698 | -1.553 | -2.88 | -3.49 | -4.99 | -13.09 | -7.17 |
| EBITDA
| -11.304 | -23.735 | -69.314 | -113.666 | -80.079 | -117.797 | -57.215 | -26.377 | -13.091 |
| EBITDA ratio
| -0.056 | -0.145 | -0.629 | -2.292 | -1.615 | -5.845 | -23.211 | -16.952 | -12.178 |